Mesoblast, a Melbourne-based biotech company, began enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L for the treatment of COVID-19. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months. Yourway is equipped to handle and transport sensitive clinical trial materials, including cell and gene therapies.